Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Medtronic Valiant Captivia Demonstrates Safety and Efficacy at Three Years

Medtronic plc
Posted on: 20 Sep 16

New Clinical Data Presented in Complicated Type B Aortic Dissection at VIVA 2016

DUBLIN and LAS VEGAS - Sept. 20, 2016 -  Medtronic plc (NYSE: MDT) today announced new data, demonstrating safety and efficacy at three years in acute complicated Type B aortic dissection patients treated with the Valiant ® Captivia ® Thoracic Stent Graft System. Ali Azizzadeh, MD, FACS, University of Texas Health Science Center in Texas presented the new clinical data in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2016.

An acute aortic dissection is a serious condition in which the inner layer of the aorta tears, blood surges through the tear, and causes the inner and middle layers of the aorta to separate. This can result in aorta rupture or malperfusion of the vessels originating from the dissected aorta, leading to high morbidity and mortality.  A type B dissection is a tear located in the descending aorta.

"Evidence shows that patients with acute complicated Type B aortic dissections can be safely and effectively treated with thoracic endovascular aortic repair (TEVAR)," said Dr. Azizzadeh. "The Valiant Captivia System continues to produce positive outcomes through three years in a very challenging patient population."

The FDA-approved Valiant Captivia System demonstrates continued safety and efficacy at three years. The data were gathered on 50 patients in the Medtronic Valiant Captivia Dissection IDE Trial, conducted at 16 U.S. sites.

Data highlights through three-year follow-up:

  • Freedom from all-cause mortality was 79.4 percent
  • Freedom from dissection-related mortality was 90.0 percent
  • No post-index procedure ruptures or conversions
  • True-lumen diameter over the stented region remained stable or increased in 92.3 percent, false-lumen diameter remained stable or decreased in 69.2 percent, and the false lumen was partially or completely thrombosed in 75.0 percent of patients
  • Three patients required secondary endovascular procedures related to the dissection

"Medtronic is committed to working with physicians to treat more complex aortic disease and improve the lives of patients," said Daveen Chopra, vice president and general manager of the Aortic business, which is part of the Aortic & Peripheral Vascular division at Medtronic. "The Valiant line of technology leverages decades of clinical experience in continuing to treat thoracic disease and has been used to treat more than 75,000 patients."

In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic

Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Contacts:
Krystin Hayward
Public Relations
+1-508-261-6512

Ryan Weispfenning
Investor Relations
+1-763-505-4626



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medtronic plc via GlobeNewswire
HUG#2042607
GlobeNewswire
globenewswire.com

Last updated on: 21/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.